Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • Blog
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • Blog
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. Cell lines and Normal Cells
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

Cell lines and Normal Cells

[0870-ABC-TC3791] HUMAN RETINAL PIGMENT EPITHELIAL CELLS
HUMAN RETINAL PIGMENT EPITHELIAL CELLS
3,264.00 € 3264.0 EUR
[-0870ABM-TM3746] HUMAN PANCREATIC STELLATE CELLS Medium Test
HUMAN PANCREATIC STELLATE CELLS Medium Test
816.00 € 816.0 EUR
[0870-ABC-TC3746] HUMAN PANCREATIC STELLATE CELLS , 1 vial
HUMAN PANCREATIC STELLATE CELLS , 1 vial
3,040.00 € 3040.0 EUR
[0870-ABC-TC4286] HUMAN PANCREATIC  SLETS OF LANGERHANSCELLS
HUMAN PANCREATIC SLETS OF LANGERHANSCELLS
3,808.00 € 3808.0 EUR
[0870-ABM-TM4286] HUMAN PANCREATIC  SLETS OF LANGERHANS CELLS Medium Test
HUMAN PANCREATIC SLETS OF LANGERHANS CELLS Medium Test
1,025.00 € 1025.0 EUR
[0870-ABC-TC3744] HUMAN PANCREATIC  EPITHELIAL CELLS
HUMAN PANCREATIC EPITHELIAL CELLS
3,488.00 € 3488.0 EUR
[0870-ABM-TM3743] HUMAN OVARIAN  SURFACE EPITHELIALCELLS Medium Test
HUMAN OVARIAN SURFACE EPITHELIALCELLS Medium Test
900.00 € 900.0 EUR
[0870-ABC-TC3743] HUMAN OVARIAN  SURFACE EPITHELIAL CELLS
HUMAN OVARIAN SURFACE EPITHELIAL CELLS
3,660.00 € 3660.0 EUR
[0870-ABC-TC3879] HUMAN INTESTINAL EPITHELIAL CELLS , 1 vial
HUMAN INTESTINAL EPITHELIAL CELLS , 1 vial
3,360.00 € 3360.0 EUR
[0870- ABC-TC5463] HUMAN DOPAMINERGIC NEURON CELLS
HUMAN DOPAMINERGIC NEURON CELLS
3,569.00 € 3569.0 EUR
[0089-HEC02] HUMAN BRAIN MICROVASCULAR ENDOTHELIAL CELLS, 1 vial
HUMAN BRAIN MICROVASCULAR ENDOTHELIAL CELLS, 1 vial
1,679.00 € 1679.0 EUR
[0171-T9279] HPV-16 E6/E7 Stable Expression Hacat Cell Line Clone #11 - 1x106 cells / 1.0 ml
HPV-16 E6/E7 Stable Expression Hacat Cell Line Clone #11 - 1x106 cells / 1.0 ml
7,020.00 € 7020.0 EUR
[0171-T1192] HK-2 Cells
HK-2 Cells
2,150.00 € 2150.0 EUR
[0171-T6297] HIF HRE-Luc/LacZ Stable Expressing B16LS9 Mouse Melanoma Cell Line - 1x10⁶cells / 1.0 mL
HIF HRE-Luc/LacZ Stable Expressing B16LS9 Mouse Melanoma Cell Line - 1x10⁶cells / 1.0 mL
11,035.00 € 11035.0 EUR
[0500-SC007] HEK293-RFP stable cells - 1 vial x (2 x 10^6 cells)
HEK293-RFP stable cells - 1 vial x (2 x 10^6 cells)
1,170.00 € 1170.0 EUR
[0683-T0005011] HBEC-5i cells
HBEC-5i cells
927.00 € 927.0 EUR
[0683-C0016020] H596 cells
H596 cells
826.50 € 826.5 EUR
[0683-C0016019] H441 cells
H441 cells
826.50 € 826.5 EUR
[0893-ACC-102] GV3101 (pSoup-p19) Chemically Competent Cells - 10 tubes (100μL/tube)
GV3101 (pSoup-p19) Chemically Competent Cells - 10 tubes (100μL/tube)
916.00 € 916.0 EUR
[0893-ACC-111-10tubes] GV3101 (pSoup) Chemically Competent Cells - 10 tubes (100μL/tube)
GV3101 (pSoup) Chemically Competent Cells - 10 tubes (100μL/tube)
995.00 € 995.0 EUR
  • 1
  • 2
  • 3
  • 4
  • 5

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)